Blog

A single failed shipment in the cell and gene supply chain does not mean a refund or a reorder. It means a patient loses their only manufactured dose of a therapy that took weeks to produce from their own cells. That is the reality every sponsor, CDMO, and hospital pharmacy is dealing with when they hand a cryopreserved bag of CAR-T cells or a viral vector shipment to a courier. If you are reading this, you are probably past the research stage. You know cell and gene logistics is different from regular pharma freight, and you are trying to figure out which provider can actually handle it without turning your shipment into a case study in what went wrong. This guide walks through what a serious cell and gene supply chain partner needs to bring to the table, the standards they must meet, and the specific capabilities that separate a general cold chain courier from one built for advanced therapies. What the Cell and Gene Supply Chain Actually Covers The cell and gene supply chain is the full sequence of steps that move a living or genetically modified biological product from collection to infusion. For autologous therapies, that starts with apheresis at a clinical site, continues through cryopreservation, transport to a manufacturing facility, processing, and then a return trip back to the same patient. For allogeneic therapies and viral vectors, the chain runs from manufacturing site to hospital or clinic, often across borders. Every one of these steps carries risk that does not exist in traditional pharmaceutical distribution. A vial of insulin that drifts a few degrees off spec might lose potency. A cryopreserved cell therapy product that warms even briefly outside its validated range can become unusable, and because many of these products are made from a specific patient’s own cells, there is no replacement batch sitting in a warehouse. Our <a href=”https://stccouriers.in/solutions/cell-and-gene-supply-chain/”>cell and gene supply chain</a> service was built around this exact problem, treating each shipment as a one-of-one event rather than a routine parcel. Why This Supply Chain Behaves Differently From Standard Pharma Logistics Most pharmaceutical logistics providers know how to hold a shipment at 2°C to 8°C. That is a solved problem. Cell and gene products introduce three layers of difficulty that standard cold chain providers were never built to manage. Ultra-Low and Cryogenic Temperature Ranges Depending on the product, shipments may need to stay anywhere from -20°C down to -196°C in vapor-phase liquid nitrogen. Cryopreserved cell therapies typically sit at the coldest end of that range, while some gene therapy intermediates ship frozen between -65°C and -80°C. A courier that only operates refrigerated trucks and dry ice coolers simply cannot serve this market. Passive shippers rated for cryogenic transport, backed by validated thermal performance data, are non-negotiable. Chain of Identity, Not Just Chain of Custody Standard pharma shipments need chain of custody, a record of who held the product and when. Autologous cell therapies need chain of identity as well, meaning the exact patient-specific material must be tracked and matched at every single handoff, with zero tolerance for mix-ups. A courier that treats this as an afterthought is not equipped for the category. Overlapping Regulatory Frameworks A single shipment can sit under FDA 21 CFR Part 1271 governing human cells and tissue-based products, IATA Dangerous Goods Regulations if the material is classified as a biological substance, and Good Distribution Practice rules in the destination country, all at once. These frameworks do not apply one after another. They apply simultaneously, and a logistics partner needs systems built to satisfy all of them on the same shipment. The Real Cost of a Broken Link It helps to be direct about what failure looks like here. A temperature excursion on a CAR-T shipment can mean the patient restarts apheresis and waits weeks for a new manufacturing slot, assuming their disease allows for that delay. A misrouted shipment crossing a border without the right permits can sit in customs long enough to exceed the product’s validated shipping window. A documentation gap discovered during an audit can jeopardize a clinical trial site’s certification. None of these are hypothetical. They are the reasons manufacturers and hospital systems are increasingly selective about who touches their cell and gene shipments, and why the vetting process for a logistics partner now looks a lot like vetting a manufacturing vendor. If your organization is running <a href=”https://stccouriers.in/solutions/clinical-trial-logistics/”>clinical trial logistics</a> alongside commercial supply, the stakes multiply, since a single courier failure can affect both a patient outcome and trial data integrity. The Regulatory Standards Governing This Category Any provider you evaluate should be able to speak fluently about the following, without needing to look it up mid-conversation. FDA 21 CFR Part 1271 governs human cells, tissues, and cellular and tissue-based products in the United States, setting donor eligibility, current good tissue practice, and traceability requirements that extend into how these products move between facilities, as detailed directly by the <a href=”https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271″ target=”_blank” rel=”noopener”>Electronic Code of Federal Regulations</a>. FDA’s evolving CMC flexibility framework matters too. In January 2026, the FDA announced it is sharing information about the agency’s flexible approach to overseeing chemistry, manufacturing and control requirements for cell and gene therapies, calling the changes helpful for expediting product development ahead of a Biologics License Application submission, according to the <a href=”https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/flexible-requirements-cell-and-gene-therapies-advance-innovation” target=”_blank” rel=”noopener”>FDA’s own guidance page</a>. A faster path to approval means more products moving through the supply chain sooner, which raises the bar on logistics readiness rather than lowering it. IATA CEIV Pharma certification addresses the air cargo side of the equation. The program was created because, as IATA explains, the pharmaceutical industry relies on air transport for its speed, consistency and efficiency in ensuring high-value, time-sensitive, temperature-controlled products reach their destination safely, and certification confirms that facilities, equipment, operations, and staff meet the standards pharmaceutical manufacturers actually expect. Full details are available on <a href=”https://www.iata.org/en/services/certification/special-cargo/ceiv-pharma/” target=”_blank” rel=”noopener”>IATA’s CEIV Pharma program page</a>. EU Good Distribution Practice and equivalent regional frameworks apply the moment a

Choosing the wrong provider for clinical trial supply services does not show up as a line item on an invoice. It shows up as a delayed site activation, a temperature excursion on a biologic shipment, a customs hold that pushes a first-patient-in date back by three weeks, or a deviation report that a monitor flags during an audit. If you are evaluating vendors right now, you already know the stakes. This guide is written for sponsors, CROs, and clinical operations teams who are past the research stage and need a clear framework for picking a supply and logistics partner that will not become the weak link in the trial. What Clinical Trial Supply Services Actually Cover The phrase gets used loosely, so it helps to be precise about scope. Clinical trial supply services span the full journey of an investigational product and trial-related material from the manufacturing or depot site to the patient, and often back again for reconciliation and destruction. That includes primary and secondary packaging, labeling and blinding, storage at the required temperature band, transportation across one or more borders, site delivery, ancillary supply kitting, and the reverse logistics needed to return or destroy unused product. A provider offering true clinical trial supply chain management is not just moving boxes. They are managing chain of custody documentation, temperature data for every leg of the journey, import and export permits, and the site-level receipt confirmations that auditors will ask for months or years later. Miss any one of these and the data generated from that shipment can be questioned, which is a far bigger problem than a late delivery. If your current process treats packaging, storage, and transport as separate vendor relationships, you already understand the coordination tax that creates. That is usually the first thing sponsors fix when they move to a dedicated clinical trial supply and logistics partner. Why Clinical Trial Supply Chain Management Breaks Down Most supply chain failures in clinical trials trace back to one of three causes: a handoff between vendors with no single point of accountability, a temperature excursion that was not caught until the shipment reached the site, or a documentation gap that surfaces during a monitoring visit or regulatory inspection. ICH-GCP places clear responsibility on the sponsor for the supply, accountability, and disposition of investigational product, and expects an accurate, timely record of every movement to be available for inspection. That obligation does not disappear because a courier is handling the physical movement. If the courier’s temperature log has a gap, or a customs delay pushes a shipment outside its validated excursion window, the sponsor still owns the consequence. This is why clinical trial supply chain management has to be evaluated as a compliance function first and a transportation function second. A provider who is fast but cannot produce a defensible audit trail is not actually solving your problem, they are postponing it to your next FDA or EMA inspection. What Separates Serious Clinical Trial Logistics Companies From the Rest Not every courier that claims cold chain capability is equipped to handle investigational product. Here is what actually distinguishes the providers worth signing with. Temperature Control and Cold Chain Capability Investigational products, especially biologics, vaccines, and cell and gene therapies, are frequently stable only within a narrow temperature band. A provider needs validated packaging systems, calibrated monitoring devices, and vehicles that maintain the required range across the entire route, not just the first leg. Ask any prospective vendor how they handle a documented excursion mid-transit and what their real average response time looks like, not their stated SLA. Our cold chain logistics team, for example, builds route-specific temperature mapping before a single shipment moves, which is the same principle regulators expect to see documented. Regulatory and GCP Compliance Good Distribution Practice is not optional guidance, it is the baseline regulators check against during inspection. WHO’s GDP framework requires that pharmaceutical products, including biologicals and vaccines, be distributed under conditions that preserve their original quality throughout the chain, and it applies whether the product is prescription only or over the counter. A provider that cannot walk you through their GDP-aligned SOPs before you sign is not a provider you want holding your investigational product. Our regulatory compliance practice is built around exactly this expectation, from documentation retention to import and export permitting. It is also worth noting that the regulatory bar keeps moving. According to UCSF’s Office of Ethics and Compliance, ICH’s revised E6(R3) guideline was adopted by FDA in September 2025, and ISO 14155 was updated again in March 2026, so a supply partner working from a five-year-old playbook is already behind current expectations. This matters more than it sounds. Auditors reference the current version of these standards, not the version your provider trained on three years ago, and a documentation gap tied to an outdated SOP is one of the more common findings in inspection reports. Packaging and Validation Validated packaging is the difference between a shipment that survives a summer tarmac delay and one that does not. This means qualified insulated shippers, phase change material or dry ice configurations matched to the product’s stability profile, and documented validation studies behind every packaging configuration used. Our packaging technology team validates configurations against real transit conditions rather than lab-only assumptions, which is where a lot of off-the-shelf packaging quietly fails. Global Reach and Customs Expertise Multi-site, multi-country trials are now the norm rather than the exception, and every border crossing introduces a new customs regime, import permit requirement, and potential delay. A partner without dedicated pharma customs expertise in the countries your trial actually operates in will cost you time at exactly the wrong moment, usually during site activation or an unplanned resupply. Real-Time Visibility and Technology Clinical operations teams need to know where a shipment is and what temperature it has held, not after delivery, but while it is in transit. Real-time tracking with automated excursion alerts lets your team intervene before a shipment fails, rather than filing a

Pharmaceutical regulatory compliance in cold chain shipping is not a paperwork exercise you complete after a shipment leaves the warehouse. It is the difference between a batch of insulin reaching a hospital in usable condition and that same batch getting quarantined at a port because a temperature log has a gap in it. Every stakeholder in the chain, from the manufacturer to the last-mile courier, carries legal responsibility for keeping a medicinal product within its approved conditions from release to delivery. If you are evaluating a logistics partner for pharma, biotech, or clinical trial shipments right now, this article gives you the exact criteria regulators check and the questions you should be asking before you sign anything. What Pharmaceutical Regulatory Compliance Actually Covers Pharma regulatory compliance in logistics sits at the intersection of three obligations: product quality, legal documentation, and traceability. A shipment can fail an audit even when the medicine itself arrives physically intact, because inspectors are checking whether the process that moved it followed a documented, repeatable, and verifiable standard. This means compliance covers temperature control during transit, the accuracy of customs and hazard classification, the completeness of shipping documentation, the training record of the personnel handling the product, and the ability to reconstruct the entire journey of a shipment on demand. A courier who delivers on time but cannot produce a validated temperature log, a signed chain-of-custody record, or proof of GDP training for the driver has not met the compliance bar, regardless of the delivery outcome. For companies moving vaccines, biologics, active pharmaceutical ingredients, or clinical trial materials, this standard applies to every leg of the journey, including domestic transfers between warehouses and last-mile delivery to a hospital or trial site. Why a Compliance Failure Costs More Than a Fine A regulatory lapse in pharmaceutical logistics rarely stays contained to one shipment. When a temperature excursion goes undetected or a customs declaration is filed incorrectly, the consequences extend into the sponsor’s or manufacturer’s own license standing. Regulators can suspend an import license, force a product recall, or place a facility under increased inspection frequency after repeated non-conformances traced back to distribution. For manufacturers running under India’s revised Schedule M, inspection activity has already intensified through late 2025 and into 2026 as the Central Drugs Standard Control Organisation moves state authorities toward stricter enforcement of GMP requirements across the supply chain, distribution included. A logistics failure that surfaces during one of these inspections becomes the manufacturer’s problem, not just the courier’s. There is also a patient safety dimension that no compliance program can treat as secondary. A vaccine that spends four hours outside its approved 2 to 8 degree Celsius range may lose potency without any visible change, which is exactly why regulators demand continuous, validated monitoring rather than a visual check at delivery. The commercial cost compounds quickly once a compliance issue surfaces publicly. Hospital networks, distributors, and clinical trial sponsors now run their own vendor audits before renewing a logistics contract, and a documented non-conformance from a regulator becomes part of that vendor file for years. Losing a long-term pharma client over a preventable documentation gap tends to cost far more than the investment needed to close that gap in the first place. Insurance underwriters covering cargo also price temperature-sensitive shipments differently once a provider has a history of excursions, which raises the operating cost of every future shipment, not just the one that failed. The Regulatory Frameworks Every Pharma Shipment Has to Satisfy CDSCO and the Revised Schedule M Standard In India, the Central Drugs Standard Control Organisation sets the baseline for how pharmaceutical products must be manufactured, stored, and distributed under the Drugs and Cosmetics Act. The revised Schedule M brought Indian GMP requirements closer to WHO and international standards, adding explicit expectations around quality risk management, computerised systems, and lifecycle validation. CDSCO has been running phased compliance deadlines through 2025 and 2026, with inspections targeting manufacturers who delayed the upgrade. A distribution partner operating in this environment needs to understand how CDSCO’s regulatory framework intersects with transport, because a manufacturer’s own audit readiness now depends partly on the paper trail their logistics provider can produce. WHO Good Distribution Practice Good Distribution Practice, as laid out in WHO Technical Report Series Annex 5, is the reference framework most national regulators build on. GDP requires a documented quality system, risk assessment before storage or transport, calibrated and traceable monitoring equipment, and a formal process for investigating and closing out any deviation. It applies to every party in the distribution chain, not only the manufacturer, which is why logistics providers working in pharma are expected to hold their own GDP-aligned quality system rather than simply following instructions handed down to them. FDA DSCSA for US-Bound Shipments Shipments moving into or through the United States fall under the Drug Supply Chain Security Act. The law requires interoperable, electronic tracing of prescription drugs at the package level across every trading partner, with the final enforcement phase for smaller dispensers landing in November 2026. For a courier or freight forwarder, this means transaction data, chain-of-custody records, and verification responses need to be retrievable within a short window if the FDA or a trading partner requests them. Manual, paper-based tracking no longer satisfies this requirement. EU GDP and IATA CEIV Pharma Within the European Union, distribution of medicinal products is governed by the Guidelines on Good Distribution Practice of Medicinal Products for Human Use, published in the Official Journal, which set out wholesaler and transport obligations for storage, temperature mapping, and prevention of falsified medicines entering the legal supply chain. For air freight specifically, IATA’s CEIV Pharma certification has become the recognized benchmark for airlines, ground handlers, and freight forwarders handling temperature-sensitive pharma cargo, covering everything from packaging validation to staff competency. What a GDP-Compliant Logistics Partner Has to Prove Documentation and Chain of Custody Every pharmaceutical shipment needs a complete paper and digital trail: pro-forma invoices, air waybills or consignment notes, dangerous goods declarations where applicable, and

Cold chain packaging is the single decision that determines whether a temperature sensitive shipment reaches its destination usable or ruined. Vaccines, biologics, reagents, blood products and specialty drugs do not fail because of bad roads or delayed flights. They fail because the packaging around them could not hold the required range long enough. If you are evaluating cold packaging for an upcoming shipment, or trying to fix a pattern of temperature excursions, this guide walks through what actually works, what to check before you commit to a vendor, and how STC Couriers builds cold chain packaging solutions around the product rather than the other way around. This is written for the person who already understands the stakes. You are not here to learn what “cold chain” means in the abstract. You are here to pick a packaging approach and a logistics partner that will not let you down on the next shipment. Why Cold Chain Packaging Decides the Outcome, Not the Vehicle A refrigerated truck or a temperature controlled warehouse only protects a shipment while the product sits inside them. The moment a package leaves the truck, moves through a tarmac, sits at a customs checkpoint, or waits on a loading dock in Chennai in May, the packaging is the only thing standing between the product and the ambient temperature outside. Good cold chain packaging is designed to absorb exactly those gaps. This matters because most temperature excursions do not happen during transit itself. They happen during handoffs. A shipment moves from a warehouse to a vehicle, from that vehicle to an airport, from the airport to another vehicle, and finally to the receiving facility. Each handoff is a point where the product is briefly outside active climate control. Packaging that has not been validated for the full duration of these gaps will fail exactly when it matters, even if every other part of the logistics chain performed correctly. For pharmaceutical and life sciences companies, this is not a minor operational detail. Regulatory bodies treat it as a core compliance requirement. India’s Guidelines on Good Distribution Practices for Pharmaceutical Products, issued by CDSCO, require that products showing signs of a specified environmental deviation, such as temperature, be identified and quarantined without delay. That single requirement puts the burden squarely on packaging performance, because a poorly designed cold pack cannot prove it held the required range, and a shipment that cannot prove its temperature history is treated as compromised whether or not it actually was. The Real Cost of Getting Cold Packaging Wrong A failed cold chain shipment rarely shows up as an obvious, visible problem. Vaccines that have been exposed to heat do not change color or smell different. Biologics that have partially degraded still look identical to a healthy batch. This is exactly why the financial and regulatory damage is so severe. Companies discover the failure only after potency testing, after a clinical trial site rejects a batch, or worse, after a patient receives a compromised dose. Beyond the cost of the wasted product, there is the cost of the investigation. Every temperature excursion triggers a deviation report, a root cause analysis, and in regulated industries, documentation that has to satisfy an auditor. If packaging was not validated for the actual transit profile, that investigation drags on because nobody can say with confidence where the failure occurred. This is the difference between a five minute conversation with a data logger printout and a multi week investigation that delays a product launch or a clinical trial milestone. There is also a reputational cost that is harder to quantify but easier to lose. A distributor, hospital network or clinical research organization that receives a compromised shipment once will start asking pointed questions about your packaging validation before they place a second order. In an industry where trust is the actual product being sold, one packaging failure can cost far more than the shipment itself. Types of Cold Chain Packaging Solutions Not every shipment needs the same packaging approach. The right choice depends on the required temperature range, the transit duration, the shipment volume and the level of documentation the receiving party expects. Broadly, cold chain packaging solutions fall into three categories. Passive Packaging Systems Passive packaging relies on insulation and a pre-conditioned thermal mass, usually gel packs, phase change material or dry ice, to hold a temperature range without any external power source. These systems are the most widely used because they are cost effective, do not require charging or monitoring hardware, and work well for shipments that stay within a predictable transit window, typically 24 to 120 hours depending on the design. The limitation with passive systems is that their performance is only as good as their validation. A gel pack qualifier that has been tested at 25 degrees ambient will not necessarily perform the same way during a Delhi summer tarmac delay at 45 degrees. This is why passive packaging needs to be selected and tested against the actual lane and season, not a generic specification sheet. Active Packaging Systems Active packaging uses powered refrigeration or heating units built into the container itself, giving it the ability to maintain a set point regardless of external temperature swings. These are the right choice for high value biologics, cell and gene therapy materials, or any shipment where the cost of failure far exceeds the cost of the packaging itself. Active containers also tend to include built in temperature logging, which removes the guesswork during a compliance review. The tradeoff is cost and logistics complexity, since these units are heavier, require battery management, and often need to be returned to the sender after use. Hybrid Packaging Systems Hybrid systems combine passive insulation with a smaller active component, often a solid state or Peltier based temperature control unit layered inside a passive shell. This approach has gained traction for mid duration shipments where full active refrigeration is not cost justified but a purely passive system does not offer enough of a safety

A pharmaceutical shipment can be packed properly, collected on time and still face a temperature excursion before reaching its destination. A delayed handover, unexpected traffic, airport hold, missed delivery window or equipment issue can expose a product to conditions outside its approved range. For pharmaceutical, biotech and life sciences businesses, the key question is not whether a disruption can ever happen. It is whether the shipment has been planned well enough to reduce the chance of an excursion and whether there is a clear process to respond if one occurs. This guide explains what a temperature excursion is, why it matters, how businesses can reduce the risk and what should happen when a pharmaceutical shipment does not follow its planned temperature profile. What Is a Temperature Excursion? A temperature excursion occurs when a product is exposed to conditions outside its defined storage or transport range. The required range depends on the product. Some products need refrigerated conditions, some require frozen movement and others need controlled ambient handling. Not every temperature event has the same impact. The significance depends on the product, the degree of variation, the length of exposure and the product’s approved stability information. However, every excursion should be treated seriously and assessed through the shipper’s quality process, in line with recognised frameworks such as the WHO Model Guidance on the Storage and Transport of Time- and Temperature-Sensitive Pharmaceutical Products and the EU Guidelines on Good Distribution Practice. The logistics provider’s role is to help prevent avoidable events, maintain clear records and communicate quickly if a shipment does not move as planned. Why Temperature Excursions Matter in Pharma Logistics Temperature-sensitive pharmaceutical products may be affected when they are exposed to unsuitable conditions. A product may not show any visible change after an excursion, which is why monitoring and documentation are so important. An excursion can create delays in product release, lead to quality review, affect customer supply and increase operational cost. For high-value products, clinical materials or patient-specific shipments, the impact can be even greater. Good cold chain logistics does not only focus on keeping a shipment cold. It focuses on protecting the product’s required conditions through storage, packaging, transit, handovers and final delivery. This is especially critical for life sciences logistics, where product stability requirements are often stricter than in general pharma distribution. Common Causes of Temperature Excursions Many excursions are linked to process gaps rather than one major failure. A shipment may be ready for pickup before the vehicle arrives. It may be held in an unsuitable location during loading. The packaging may not be designed for the real transit duration. The receiving team may not be ready when the delivery vehicle reaches the destination. Traffic, weather, delayed flights, customs holds, vehicle issues and missed connections can also affect the planned route — particularly for shipments moving through global logistics networks that cross multiple handovers and jurisdictions. These risks cannot always be removed, but they can be considered before dispatch. The most reliable cold chain plan is based on realistic operating conditions. It allows time for possible delay and includes clear instructions for each stage of the shipment. For a deeper look at how these risks play out in India specifically, see our guide to temperature controlled logistics in India. Prevention Begins Before Pickup The best way to manage a temperature excursion is to reduce the chance of one before the shipment moves. This begins with a clear shipment plan, whether the product is moving through a standard pharmaceutical supply chain or a more specialised route such as clinical trial logistics or the cell and gene supply chain. The logistics partner should understand the product’s required temperature range, packaging need, route, pickup time, transit window, destination conditions and final delivery schedule. A service should not be selected only because it is the fastest available option. It should be selected because it is appropriate for the shipment. Before pickup, businesses should confirm that the product is held in suitable storage, the packaging is ready, the vehicle or courier is scheduled, the receiving team knows the expected delivery time and the required documents are complete. Documentation gaps are one of the most common causes of avoidable delay — see our guide on pharmaceutical logistics compliance, GDP, customs and shipping documentation for more detail. Packaging Must Support the Real Journey Packaging technology protects a pharmaceutical product from external conditions during handling and movement. But the right packaging decision depends on more than the product’s stated temperature range. It must also reflect the actual route. A shipment travelling by road within one city has different risks from a domestic air shipment or an international movement with customs clearance. Highly sensitive products, such as those requiring cryogenic transportation, need packaging validated for far longer holdover times than standard 2–8°C shipments. The packaging should support the expected transit window and account for reasonable delays. Businesses should work with a logistics provider that understands validated packaging technology and can recommend a solution suited to the route. The packaging must be chosen before the shipment is collected, not after a delay has already occurred. The Importance of Temperature Monitoring Temperature monitoring provides a record of what happened during storage and transit. Data loggers and monitoring tools can help a shipper understand whether the product stayed within its required range and identify the timing of a possible deviation. Platforms such as STC Couriers Connect are built to give shippers this kind of real-time visibility across a shipment’s journey. Before dispatch, agree on the monitoring approach. Confirm whether a data logger will travel with the shipment, what information will be available after delivery and who is responsible for reviewing the data. Monitoring is useful even when a shipment is completed without issue. It gives the customer confidence that the movement was managed according to plan. If an event occurs, it gives the quality team a factual record to support its assessment. Shipment Visibility Helps Teams Respond Faster Temperature control and shipment visibility should work together. A

Life sciences shipments cannot be treated like ordinary freight. Medicines, clinical trial materials, biotech samples and medical devices may need controlled temperatures, careful documentation and clear handover records. A delay, handling error or missing document can affect a study, a product release or a planned delivery. At CFKR STC Couriers, we support businesses that need a more controlled approach to movement, packaging and delivery. Our life sciences logistics service is built around planning the shipment properly before collection, maintaining visibility while it moves and completing delivery with the required records. The right logistics plan depends on the product, temperature range, route, destination, urgency and applicable regulations. This is why pharmaceutical logistics and healthcare logistics need more than a standard courier booking. Why life sciences logistics needs a planned process Life sciences logistics covers the movement of sensitive products used in pharmaceutical, healthcare, biotech and research environments. These shipments can include medicines, diagnostic items, clinical trial materials, devices, samples and other controlled products. Each shipment should start with a clear assessment. The logistics team needs to understand what is being shipped, where it is going, what conditions it needs during transit and what documents are required. This helps avoid last-minute changes that can delay collection or customs clearance. The World Health Organization explains that storage and distribution are important parts of medical-product supply chain management, as products can face risks during transport, storage, repackaging and distribution. Its guidance also notes that every party in the supply chain must follow applicable legislation and regulations. Read the WHO good storage and distribution practices guidance. For this reason, reliable life sciences logistics must combine operational planning, controlled handling, shipment tracking and regulatory compliance. Shipment tracking from collection to delivery confirmation Shipment tracking gives the shipper visibility after the consignment leaves the facility. For sensitive products, a tracking number alone is not enough. The process should also include planned checkpoints, clear escalation when an exception occurs and a confirmed record when the consignee receives the shipment. A strong shipment tracking process starts at collection. The shipment details, destination, contact persons, handling requirements and documents should be checked before dispatch. During transit, the team should be able to monitor the shipment status and respond quickly if there is a routing issue, a missed connection or a delivery concern. At the final stage, delivery confirmation provides evidence that the shipment has reached the intended consignee. This may include the delivery time, recipient details and proof of handover, based on the service and shipment requirements. For pharmaceutical distribution, this visibility helps the sender coordinate with hospitals, laboratories, distributors, trial sites and receiving teams. It also helps reduce uncertainty when the shipment is urgent or time-sensitive. Cold chain logistics for temperature-sensitive shipments Cold chain logistics is used when a product must stay within a defined temperature condition during storage and transport. The right solution depends on the product’s approved temperature range, expected transit time, route conditions and packaging performance. Temperature-controlled logistics is not one fixed service. Some shipments may need chilled conditions, while others may require frozen conditions or a much lower temperature range. The packaging choice must support the required condition for the expected journey, including handling time at collection, airport or transit points and final delivery. STC Couriers’ Cold Chain service can be considered where a shipment needs controlled movement and a planned cold chain process. Before booking, share the product handling instructions, temperature requirement, package dimensions, shipment value, destination and required delivery time. Temperature-controlled packaging helps create the required protection around the product during transit. Cold chain packaging may include qualified insulated packaging, refrigerants and handling instructions selected for the shipment profile. Packaging must be matched to the actual route and product requirement; using a standard box without assessment can create avoidable risk. Cold chain distribution should also consider the handover points. A shipment can be well packed but still face problems if the receiving location is not ready, if the contact person is unavailable or if there is no clear delivery procedure. Good planning covers the full journey, not only the transport leg. Pharmaceutical logistics and pharmaceutical cold chain logistics Pharmaceutical logistics requires careful coordination because products may be subject to quality requirements, controlled temperatures, traceability needs and destination-specific rules. A practical process begins with understanding whether the shipment is ambient, chilled, frozen or otherwise temperature-sensitive. Pharmaceutical cold chain logistics adds another layer of responsibility. The product’s temperature requirement must be understood before packaging and routing are selected. The shipper should provide the handling instructions and any supporting documents needed for the shipment. For pharmaceutical distribution, it is useful to confirm these points before collection: Product description and intended use Required storage and transport conditions Origin and destination details Required delivery date and receiving hours Packaging and refrigerant requirement Regulatory compliance and customs documentation needs Contact details for both sender and consignee Delivery confirmation requirement This information allows the logistics partner to plan a suitable service instead of treating the shipment as ordinary cargo. Clinical trial logistics for time-sensitive study materials Clinical trial logistics requires close coordination between sponsors, clinical research organisations, sites, laboratories and logistics teams. Clinical trial materials may include investigational products, kits, samples, documents or other study-related consignments. The key challenge is that each movement may have a strict timeline and site-specific delivery requirement. A clinical site may accept deliveries only during certain hours. A laboratory may require prior notice. A product may need controlled conditions until handover. Before arranging clinical trial logistics, the shipper should confirm the shipment schedule, site contact, packaging requirement, import permissions if applicable and emergency contact process. The consignee should also know that the shipment is arriving and be prepared to receive it. STC Couriers can help customers plan these shipment requirements through its Life Sciences Logistics service. Early planning is important, especially for international routes, temperature-controlled products and urgent site deliveries. Liquid nitrogen transport and dry ice transport Liquid nitrogen transport and dry ice transport need specialised planning. These materials may be used to maintain

A pharmaceutical shipment can be packed correctly and still face a delay because its documents contain conflicting information. It can also clear customs without providing the evidence needed to confirm that its required transport conditions were maintained. These are different problems, but both need attention before collection. For pharmaceutical manufacturers, biotechnology companies and clinical research organisations, regulatory compliance connects the product, its paperwork and its physical journey. Each shipment needs an appropriate classification, clear responsibilities and handling arrangements that match its requirements. At CFKR STC Couriers, we support customers with documentation, classification guidance and customised shipping procedures for pharmaceutical and life sciences logistics. This guide explains the main areas to review when preparing a shipment and choosing a logistics partner. What Does Regulatory Compliance Mean in Pharmaceutical Logistics? Regulatory compliance means meeting the requirements that apply to a particular product, shipment and route. Those requirements can involve medicinal-product controls, customs procedures, dangerous-goods rules, packaging, labelling and transport conditions. Their application depends on factors such as what is being shipped, its intended use, the countries involved and the transport method. A useful starting point is to separate three questions. Is the material legally permitted to move between the proposed locations? Will the carrier accept it under the applicable transport requirements? Can its required quality conditions be maintained throughout the journey? The shipment plan needs to address all three. Understanding Good Distribution Practice Good Distribution Practice, usually shortened to GDP, concerns the quality controls used during the distribution of medicines. For example, UK MHRA guidance explains that GDP involves obtaining medicines through the licensed supply chain and maintaining suitable storage, transport and handling conditions according to the product’s authorisation or specification. MHRA guidance on GDP For a customer evaluating pharmaceutical logistics, the practical questions concern how those principles are implemented. What procedures govern the shipment? Who checks the records? How are handling problems reported? GDP should not be confused with a universal shipping permit. Applicable licences, customs requirements and transport rules still need separate assessment. The relevant framework also depends on the jurisdiction and the activities being performed. Requirements for a medicinal product should not automatically be applied unchanged to every research sample or laboratory material. Start With Accurate Material Classification The description “pharmaceutical shipment” is too broad to determine a complete shipping process. A finished medicine, clinical trial product, biological sample and laboratory reagent may require different documentation and handling arrangements. Before requesting transport, establish the material’s identity, composition, intended use and relevant safety information. Customs Classification Customs classification determines how goods are categorised under the applicable tariff system. The World Customs Organization’s Harmonized System provides the international foundation for classifying traded goods. The applicable national tariff classification must then be checked for the shipment. WCO explanation of the Harmonized System Avoid choosing a code simply because it was used for a previous consignment. Ask the responsible customs specialist to assess the actual material and supporting information. Dangerous-Goods Classification Dangerous-goods classification addresses transport hazards. It is separate from customs classification. For air transport, IATA explains that responsibility for correct dangerous-goods classification rests with the shipper. Where information is unclear, advice should be sought from appropriate technical sources or the competent authority. IATA dangerous-goods guidance The assessment should cover the complete proposed shipment, including relevant refrigerants or accessories—not only the main product. Product and Intended-Use Requirements The purpose of the shipment should be clearly stated and supported. Is it intended for commercial supply, clinical research, laboratory testing or another authorised purpose? Who will receive it, and what will happen after delivery? These details help the responsible parties identify which permissions and procedures need review. Which Documents May Be Needed? There is no single document pack suitable for every pharmaceutical shipment. The following documents may form part of the preparation process, depending on the consignment and applicable requirements. Document or record Main purpose Commercial or pro-forma invoice, as appropriate Describes the goods, parties, quantities and relevant value information Air waybill or consignment note Records the transport arrangement and shipment details Packing list Identifies the contents and packaging configuration Import or export permissions, where required Provides evidence of the relevant authorisation Dangerous-goods declaration, where required Records the required declaration for the classified shipment Product-specific handling instructions Communicates temperature, storage and other handling requirements Monitoring and handover records Supports review of shipment conditions and transfers of responsibility The documents should tell a consistent story. Product descriptions, quantities, addresses and shipment references should agree wherever they appear. Where a dangerous-goods declaration is required, it is a substantive declaration about the shipment’s preparation—not simply an additional transport form. IATA provides guidance and formats for this document. IATA shipper’s declaration information CFKR STC Couriers supports documentation preparation and coordination. Where a document must be supplied or authorised by another party, the required responsibility should be identified early. Customs Readiness Includes More Than a Tariff Code A customs code is one part of preparation. Product descriptions, valuation, permissions and importer details also need attention. Customs valuation is a distinct process used for purposes including the calculation of duties. The World Customs Organization explains that the international framework primarily uses transaction value, subject to applicable conditions and adjustments. WCO customs valuation overview For samples supplied without charge, ask the customs representative how value should be declared under the destination’s requirements. Do not assume that describing something as “not for sale” resolves the valuation question. Before dispatch, agree who will answer customs queries and who can provide additional technical information. A nominated contact should be available during the expected clearance period. This preparation cannot guarantee clearance at a particular time, but it makes responsibilities clearer if a query arises. Temperature Control Is Part of the Compliance Plan The product’s documented requirements should determine its transport conditions. A general instruction such as “keep refrigerated” may leave important questions unanswered. The shipment brief should identify the required range, relevant time limits and any additional handling restrictions. Packaging selection should also account for the proposed journey. WHO guidance on shipping-container qualification considers factors